Medigene and Roivant affiliate Cytovant establish strategic R&D partnership for cellular therapies in Asia

Martinsried/Munich – Medigene AG (FSE: MDG1, Prime Standard) announces that the Company has entered into a multi-program license and collaboration agreement for its T cell receptor (TCR)-modified T cell therapies and a dendritic cell (DC) vaccine with Cytovant Sciences, an affiliate of the US biopharmaceutical company Roivant Sciences Ltd. Cytovant was founded by the Roivant Group as a biopharmaceutical company focused on developing and commercializing innovative cellular therapeutics in Asia. The partnership implements Medigene’s strategy of generating and out-licensing T cell immunotherapies suited for specific populations and markets.

Medigene grants Cytovant exclusive licenses to develop, manufacture, and commercialize Medigene’s research-stage T cell receptor immunotherapy targeting NY-ESO-1 as well as a DC vaccine targeting WT-1 and PRAME, in Greater China, South Korea, and Japan. In addition, Cytovant and Medigene have entered into a strategic collaboration and discovery agreement for T cell receptor immunotherapies for two additional targets. Medigene will be responsible for the generation and delivery of the TCR constructs using its proprietary TCR discovery platform. Following this research collaboration period, Cytovant will assume sole responsibility for the development and commercialization of these TCR therapies in the territories as defined above. The TCRs to be generated by Medigene will be tailored specifically to Asian patients.

Under the terms of the aforementioned transaction agreements, Medigene will receive an overall upfront payment of USD 10 million as well as potential development, regulatory, and commercial milestone payments which in aggregate could total over USD 1 billion for the four products across multiple indications. Furthermore, Medigene will be eligible to receive royalty payments on net sales of the products in a low double-digit percentage in the relevant countries. Additionally, Cytovant will reimburse all R&D costs incurred by Medigene within the collaboration.

Contractual parties to the agreement are Medigene Immunotherapies GmbH, a wholly owned affiliate of Medigene AG, and Roivant Asia Cell Therapy Holdings Ltd., a wholly owned affiliate of Roivant Sciences Ltd..

Medigene AG
Julia Hofmann, Dr. Robert Mayer
Tel.: +49 – 89 – 20 00 33 – 33 01


emitter: Medigene AG
address: Lochhamer Straße 11, 82152 Planegg
country: Germany
contact person: Julia Hofmann, Head of Public and Investor Relations
phone: +49 89 200033-3301

ISIN(s): DE000A1X3W00 (share)
stock exchanges: regulated market in Frankfurt; free market in Stuttgart, free market in Munich, free market in Hamburg, free market in Dusseldorf, free market in Hannover; open market in Berlin, Tradegate

[ source: ]